p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal Narra J Narra X
Claim Missing Document
Check
Articles

Found 2 Documents
Search

Hypoxic mesenchymal stem cell secretome upregulates IL-10 and STAT3 gene expressions in mice model with polycystic ovary syndrome Lusiana, Lusiana; Darlan, Dewi M.; Trisnadi, Setyo; Putra, Agung; Amalina, Nur D.; Husain, Sofian A.
Narra X Vol. 2 No. 3 (2024): December 2024
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narrax.v2i3.176

Abstract

Polycystic ovary syndrome (PCOS) is a condition characterized by chronic anovulation and hyperandrogenism, which often leads to infertility. It is closely associated with chronic inflammation triggered by glucose and saturated fat, contributing to hyperandrogenism and negatively impacting a patient’s quality of life. Effective therapeutic approaches are essential to address these issues. The secretome of mesenchymal stem cells (MSCs) have demonstrated the ability to suppress pro-inflammatory cytokine secretion and regulate growth factors. The aim of this study was to investigate the effect of hypoxic mesenchymal stem cell secretome (MHSSCs) on the expression of interleukin-10 (IL-10) and signal transducer and activator of transcription 3 (STAT3) genes in a PCOS-induced mouse model. An in vivo experimental study was conducted using a post-test-only control group design. A total of 24 female C57BL/6 mice were divided into four groups: healthy control, negative control (PCOS mice injected with 0.9% NaCl), T1 (PCOS mice administered 200 μL of MHSSCs), and T2 (PCOS mice administered 400 μL of MHSSCs) for 33 days. Gene expression of IL-10 and STAT3 were quantified using quantitative reverse transcription polymerase chain reaction (qRT-PCR), normalized to the expression of the housekeeping β-actin gene. Statistical analysis using one-way ANOVA followed by the least significant difference (LSD) post-hoc test was then performed. The results showed a significant increase in IL-10 expression in the T2 group compared to the negative control group (p<0.001). STAT3 expression was also significantly higher in the T2 group compared to the negative control group (p=0.035). A dose-dependent effect was observed, with the T2 group demonstrating the highest upregulation of both IL-10 and STAT3 expression levels. The study highlights that the administration of MHSSCs effectively increased IL-10 and STAT3 gene expression, suggesting their potential as a therapeutic strategy to alleviate inflammation in PCOS.
Mesenchymal stem cell-derived secretome accelerates third-degree burn wound healing: Effects on proliferation, angiogenesis, and fibrosis regulation Dirja, Bayu T.; Putra, Agung; Amalina, Nur D.
Narra J Vol. 5 No. 2 (2025): August 2025
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v5i2.1828

Abstract

Mesenchymal stem cell-derived secretome (MSC-derived secretome) has shown promise in regenerative medicine; however, research specifically evaluating its efficacy in third-degree burn wounds remains scarce. The aim of this study was to investigate the effects of MSC-derived secretome on cellular proliferation, angiogenesis, myofibroblast activity, and collagen synthesis in a third-degree burn wound model. A total of 20 Wistar rats were randomly assigned to four groups: a healthy control group, a negative control group with untreated third-degree burn wounds, and two treatment groups receiving MSC-derived secretome at doses of 100 µL and 200 µL for 14 days. The wound healing was assessed 14 days post-treatment. Proliferating cell nuclear antigen (PCNA) protein expression was quantified via Western blot to assess cell proliferation; vascular endothelial growth factor (VEGF) gene expression was analyzed using quantitative reverse transcription polymerase chain reaction (qRT-PCR) to examine angiogenesis; alpha-smooth muscle actin (α-SMA) expression was assessed through immunohistochemistry to evaluate myofibroblast activity; and collagen density was measured using Masson's trichrome staining to determine tissue remodeling.  Our data indicated that MSC-derived secretome treatment significantly enhanced multiple aspects of the healing process in a dose-dependent manner. PCNA expression increased by 2.8-fold in the 200 µL MSC-derived secretome group compared to the negative control (p<0.05). VEGF gene expression was upregulated by 2.14-fold in the 200 µL secretome group compared to the negative control (p<0.05). α-SMA protein expression increased by 12.67% in the 200 µL secretome group, while collagen density demonstrated the most pronounced improvement at the 200 µL dose, reaching an increase of 81.26% (p<0.05). In conclusion, MSC-derived secretome significantly accelerates burn wound healing by promoting cell proliferation, enhancing angiogenesis, and increasing collagen synthesis while modulating myofibroblast activity. This highlights the potential of MSC-derived secretome as a therapeutic option for optimizing burn wound repair and reducing fibrotic complications.